

(<http://aphanet.org>)

[Home](#) > First oral factor Xa inhibitor approved for DVT prophylaxis

---

**Generic Name:**

Rivaroxaban

**Trade Name:**

Xarelto

**Company:**

Bayer, Janssen Pharmaceuticals

**Notes:**

This novel oral anticoagulant is a factor Xa inhibitor that is dosed as 10 mg once daily for 35 days following hip replacement surgery and for 12 days following knee replacement surgery. According to a company [press release](#), approval was based on results from the RECORD 1, 2, and 3 studies, which compared rivaroxaban 10 mg/d with enoxaparin 40 mg/d for DVT prophylaxis following knee or hip replacement surgery. In all studies, use of rivaroxaban was associated with significantly fewer venous thromboembolic events compared with enoxaparin ( $P < 0.001$  all 3 studies). The incidences of major bleeding and any bleeding events were low in both groups and occurred at a similar rate.

**Medication Monitor Categories:**

[New Drug Approvals](#)

**Use:**

Prophylaxis of deep vein thrombosis (DVT) that may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery

---

**Source URL:** <http://aphanet.org/new-drug-approvals/first-oral-factor-xa-inhibitor-approved-dvt-prophylaxis>